A trial done to decide which among the below mentioned drugs that is either labetalol or dexmedetomidine is better at attenuating bodily responses such as heart rate and blood pressure during double lumen tube placement in a lung surgery.

A randomized trial comparing the efficacy of labetalol versus dexmedetomidine for attenuation of hemodynamic stress response in patients undergoing double lumen tube insertion. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/12/099566

Enrollment

152

Registered

2025-12-19

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J00-J99- Diseases of the respiratory system

Interventions

Intervention1: DEXMEDETOMIDINE: Dexmedetomidine 0.5mg per kg in a 50cc syringe given intravenous as a continuous infusion using syringe pump over 10 minutes prior to induction. Control Intervention1:

Eligibility

Inclusion criteria

Inclusion criteria: Patients undergoing elective lung surgery including pulmonary lobectomy pneumonectomy metastasectomy decortication who require Left sided double lumen tube placement All ASA 1to 3 patients

Exclusion criteria

Exclusion criteria: Patients with difficult airway Surgeries requiring Right sided Double Lumen tube insertion or bronchial blocker Uncontrolled hypertensives Heart disease with ejection fraction less than 50 precent Body mass index (BMI) more than 35 kg per m2, History suggestive of sensitivity to drugs used during the study Patients with bradycardia (heart rate less than 50 beat per minute) or any heart block Hepatic or renal impairment Pregnancy Patient not willing to participate in the study

Design outcomes

Primary

Measure	Time frame
To assess the effectiveness of labetalol vs dexmedetomidine for attenuation of hemodynamic stress response to double lumen tube insertionTimepoint: Heart rate and blood pressure assessed at baseline, before giving the loading dose of drug, after completion of the drug. 1 minutes interval for first 5 minutes, then 5 minutes interval for the next 30 minutes.	—

Secondary

Measure	Time frame
To assess the treatable hypotension and bradycardia during the perioperative period from the time of DLT insertionTimepoint: 1 year	—

Countries

India

Contacts

Public ContactDR KIRUBAKARAN D

CHRISTIAN MEDICAL COLLEGE VELLORE

cherrylkirubakaran@gmail.com9884858411

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026